The DILI-sim Initiative is a consortium of pharmaceutical and other life science companies centered around and led by DILIsym Services, Inc. The DILI-sim Initiative sponsors the development and application of DILIsym®, a mechanistic model of drug induced liver injury (DILI). The goals of the DILI-sim Initiative include developing the DILIsym® software and advancing the knowledge of DILI for the benefit of the scientific community and the public at-large. DILIsym® will be used during drug development, to provide enhanced understanding of the DILI hazard posed by individual molecules, and to provide deeper insight into the mechanisms responsible for observed DILI responses at various stages of the development process.